Skip to main
ANIX

ANIX Stock Forecast & Price Target

ANIX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anixa Biosciences Inc. is advancing its oncology-focused therapies, with positive Phase 1 data for its breast cancer vaccine, showing immune responses in 74% of participants, and encouraging survival signals from its ovarian cancer CAR-T therapy, lira-cel. The CAR-T therapy's selective targeting of the follicle-stimulating hormone receptor (FSHR) on ovarian cancer cells suggests a reduced risk of off-target toxicity, enhancing its therapeutic profile. These promising clinical advancements and strategic regulatory approvals bolster investor confidence and underscore Anixa's potential for significant impact in treating critical cancer indications.

Bears say

Anixa Biosciences has faced significant challenges, including a lack of commercialized products in its pipeline, which raises concerns regarding future revenue generation. The reliance on developing therapies and vaccines for high-incidence cancers places the company in a highly competitive market, where failure to secure timely clinical advancements may hinder its financial stability. Additionally, the presence of legacy operations with limited revenue contributions suggests ongoing financial strain, further reinforcing a cautious perspective on the company's overall growth outlook.

ANIX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anixa Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anixa Biosciences Inc (ANIX) Forecast

Analysts have given ANIX a Strong Buy based on their latest research and market trends.

According to 3 analysts, ANIX has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anixa Biosciences Inc (ANIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.